Lurbinectedin is a new anti-cancer drug that has shown promising results in the treatment of various types of cancer. According to Drug Patent Watch [1], Lurbinectedin is currently being studied in combination with other cancer treatments such as Doxorubicin, Paclitaxel, and Carboplatin. The combination of Lurbinectedin and Doxorubicin has been shown to be effective in the treatment of small cell lung cancer [2]. Additionally, Lurbinectedin has been studied in combination with other drugs such as Irinotecan and Cisplatin [3].

A study published in the National Library of Medicine [2] found that Lurbinectedin in combination with Doxorubicin demonstrated a synergistic effect in small cell lung cancer. Another study published in PubMed [3] found that Lurbinectedin in combination with Irinotecan and Cisplatin was well-tolerated and showed promising results in the treatment of advanced solid tumors.

Overall, the available evidence suggests that Lurbinectedin can be used in combination with other cancer treatments, and has shown promising results in the treatment of various types of cancer. However, further research is needed to determine the optimal combinations and dosages of Lurbinectedin with other drugs for different types of cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795692/
[3] https://pubmed.ncbi.nlm.nih.gov/33348988/